Dr. Beringer’s research focus is on cystic fibrosis, a genetic disorder which results in defective chloride transport within the apical membrane of epithelial cells throughout the body. The principal cause of morbidity and mortality arises from chronic pulmonary infections resulting in bronchiectasis and progressive loss of lung function and eventual respiratory failure. Dr. Beringer’s group is interested in optimizing the use of pharmacologic therapies to preserve lung function and quality of life for individuals afflicted with CF.

Ongoing research projects include: the study of the mechanistic basis of the enhanced renal clearance of antibiotics in CF; the use of novel clinical measures of glomerular filtration to improve drug dosing; and impact of pancreatic insufficiency on oral bioavailability of antibiotics.

Biography: Dr. Beringer received his Pharm.D. degree from the USC School of Pharmacy. He completed a pharmacy practice residency and specialty residency in pharmacokinetics at the University of California at San Francisco. Currently, he is an associate professor of clinical pharmacy (USC School of Pharmacy) and associate professor of clinical medicine with the department of pulmonary and critical care medicine (USC Keck School of Medicine).

Dr. Beringer's clinical expertise is in the area of cystic fibrosis pharmacotherapy. He has authored numerous journal articles and book chapters in the area of pharmacokinetics and cystic fibrosis.